2 ASX Growth Stocks to Watch: Breville Group and Pro Medicus Deliver Strong Results

BRG and PME continue to demonstrate solid growth across the consumer and healthcare technology sectors. Take a closer look at their financial results and recent developments driving investor interest

Breville Group Limited (ASX: BRG),

as on 12 February 2026, delivered strong half yearly performance with a double digit revenue growth of around 10.1% to $1.1 billion compared to prior corresponding period. The growth was driven by demand of its premium appliances and new product development.

Gross profit for the company increased by 6.3% to $389.5 million but the gross margin declined from 36.7% to 35.4% due to the impact of higher US tariffs.

The company managed to maintain its profitability despite margin pressure as the EBITDA rose by 2.9% to $182.8 million with a 0.7% in EBIT to $98.2 million. The balance sheet also improved by the end of the period as the net debt declined from $55.1 million to $43.6 million on year-on-year basis.

The company has a market capitalisation of around 4.98 billion and had also announced a fully franked interim dividend of 19 cents per share, an increment of 5.6% compared to previous year, reflecting management confidence in its cash generation.

Looking ahead, the management expects FY26 EBIT to record a slight growth but tariff uncertainty and elevated input costs remain key risks. BRG’s manufacturing diversification and premium product portfolio seems to support its long-term growth prospects, making it an attractive choice for investors in the long run.

Pro Medicus Limited (ASX: PME),

as on 12 February 2026, reported strong first half results for FY26 with revenue rising by 28.4% to $124.8 million along with an increase in underlying net profit of 29.7% to $67.3 million.

The company’s growth momentum was further supported by several other big US contract wins and renewals. PME gained a good pace in June, with the renewal of its agreement with Allegheny Health Network for five years at $28 million, adding Visage 7 Workflow. It signed another 7 year contract with TidalHealth, covering its full Visage 7 platform and cardiology imaging along with cloud implementation targeted for the first quarter of CY27.

PME also renewed a few more contracts for Workflow and Cardiology Imaging, taking FY26 contract renewals amount to $141 million.

The management had also highlighted the strong pipeline activity, a growing adoption of cardiology and AI being a potential opportunity rather than treating it as a threat.

With a market capitalisation of approximately $18.39 billion, Pro Medicus is positioned to be a premium-value healthcare technology company, with recurring contract wins and expansion into cardiology supporting its long term growth.

(Source: Company Announcements).